{"id":751244,"date":"2023-04-26T07:04:22","date_gmt":"2023-04-26T11:04:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/"},"modified":"2023-04-26T07:04:22","modified_gmt":"2023-04-26T11:04:22","slug":"cytosorbents-to-report-first-quarter-2023-operating-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/","title":{"rendered":"CytoSorbents to Report First Quarter 2023 Operating and Financial Results"},"content":{"rendered":"
\n

MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation<\/a> (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,\u00a0will report first quarter 2023 operating and financial results after the market close on Tuesday, May 2, 2023. CytoSorbents\u2019 management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day.<\/p>\n

\n
\n Conference Call Details:<\/u>
\n <\/strong>
\n
Date: Tuesday, May 2, 2023
Time: 4:30 PM Eastern
Participant Dial-In: 201-389-0879
Conference ID: 13738513
Live Presentation Webcast:
https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1612750&tp_key=e42d46cec2<\/a><\/p>\n

It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link:
https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1612750&tp_key=e42d46cec2<\/u><\/a><\/p>\n

An archived recording and written transcript of the conference call will be available under the Investor Relations section of the Company\u2019s website at http:\/\/cytosorbents.com\/investor-relations\/financial-results\/<\/a><\/p>\n

\n About CytoSorbents Corporation (NASDAQ: CTSO)<\/strong>\n <\/p>\n

\n
\n CytoSorbents Corporation<\/u>
\n <\/a> is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb\u00ae<\/sup><\/u><\/a>, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. At the end of 2022, more than 195,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor<\/u><\/a> and rivaroxaban<\/u><\/a> removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization<\/u><\/a> in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb\u2122-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, also received two FDA Breakthrough Device Designations<\/u><\/a>, one for the removal of ticagrelor<\/u><\/a> and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban<\/u><\/a> in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company is currently conducting the FDA-approved, randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 120 patients at approximately 30 centers in U.S. and Canada to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.<\/p>\n

CytoSorbents\u2019 purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $48 million\u00a0from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF\/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY\u00ae<\/sup>, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ\u00ae<\/sup>, K+<\/sup>ontrol\u2122, DrugSorb\u2122, DrugSorb\u2122-ATR, ContrastSorb, and others. For more information, please visit the Company\u2019s websites at\u00a0www.cytosorbents.com<\/u><\/a>\u00a0and\u00a0www.cytosorb.com<\/u><\/a>\u00a0or follow us on\u00a0Facebook<\/u><\/a>\u00a0and\u00a0Twitter<\/u><\/a>.\u00a0<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, , statements about potential exposures resulting from our cash positions, representations and contentions, and are not historical facts and typically are identified by use of terms such as \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue\u201d and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management\u2019s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on\u00a0March 9, 2023, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n

\n
\n Please Click to Follow Us on <\/u>
\n <\/strong>
\n
\n
\n Facebook<\/u>
\n <\/strong>
\n <\/a>
\n
\n and <\/u>
\n <\/strong>
\n
\n
\n Twitter<\/u>
\n <\/strong>
\n <\/a>\n <\/p>\n

\n U.S. Company Contact:<\/strong>
\n
Kathleen Bloch, Interim CFO
305 College Road East
Princeton, NJ 08540
+1 (732) 398-5429
kbloch@cytosorbents.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,\u00a0will report first quarter 2023 operating and financial results after the market close on Tuesday, May 2, 2023. CytoSorbents\u2019 management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day. Conference Call Details: Date: Tuesday, May 2, 2023Time: 4:30 PM EasternParticipant Dial-In: 201-389-0879Conference ID: 13738513 Live Presentation Webcast: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1612750&tp_key=e42d46cec2 It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be … <\/p>\n

Continue reading “CytoSorbents to Report First Quarter 2023 Operating and Financial Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751244","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCytoSorbents to Report First Quarter 2023 Operating and Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents to Report First Quarter 2023 Operating and Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,\u00a0will report first quarter 2023 operating and financial results after the market close on Tuesday, May 2, 2023. CytoSorbents\u2019 management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day. Conference Call Details: Date: Tuesday, May 2, 2023Time: 4:30 PM EasternParticipant Dial-In: 201-389-0879Conference ID: 13738513 Live Presentation Webcast: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1612750&tp_key=e42d46cec2 It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be … Continue reading "CytoSorbents to Report First Quarter 2023 Operating and Financial Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T11:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents to Report First Quarter 2023 Operating and Financial Results\",\"datePublished\":\"2023-04-26T11:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/\"},\"wordCount\":948,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/\",\"name\":\"CytoSorbents to Report First Quarter 2023 Operating and Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=\",\"datePublished\":\"2023-04-26T11:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents to Report First Quarter 2023 Operating and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents to Report First Quarter 2023 Operating and Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents to Report First Quarter 2023 Operating and Financial Results - Market Newsdesk","og_description":"MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,\u00a0will report first quarter 2023 operating and financial results after the market close on Tuesday, May 2, 2023. CytoSorbents\u2019 management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day. Conference Call Details: Date: Tuesday, May 2, 2023Time: 4:30 PM EasternParticipant Dial-In: 201-389-0879Conference ID: 13738513 Live Presentation Webcast: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1612750&tp_key=e42d46cec2 It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be … Continue reading \"CytoSorbents to Report First Quarter 2023 Operating and Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T11:04:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents to Report First Quarter 2023 Operating and Financial Results","datePublished":"2023-04-26T11:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/"},"wordCount":948,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/","name":"CytoSorbents to Report First Quarter 2023 Operating and Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=","datePublished":"2023-04-26T11:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTcyNiM1NTU3ODM3IzIwMjg2MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-to-report-first-quarter-2023-operating-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents to Report First Quarter 2023 Operating and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751244"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751244\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}